GlaxoSmithKline (GSK) has submitted a variation to the marketing authorisation for Votrient (pazopanib) to the European Medicines Agency. This variation is a additional indication for the maintenance treatment of women with Stage II-IV ovarian, fallopian tube or primary peritoneal cancer who have not progressed after receiving first-line chemotherapy.

“This EU filing, the third for pazopanib in less than five years, confirms GSK’s commitment to deliver our oncology pipeline. We are currently working on submission plans for other countries throughout the world,” said Dr Rafael Amado, head of Oncology R&D, GlaxoSmithKline.

Pazopanib is not approved or licensed anywhere in the world for the maintenance treatment of ovarian, fallopian tube or primary peritoneal cancer.

GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer.